Surmodics (NASDAQ:SRDX) Getting Somewhat Favorable News Coverage, Analysis Finds

Headlines about Surmodics (NASDAQ:SRDX) have been trending somewhat positive on Friday, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Surmodics earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.4831574665644 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

A number of equities research analysts have recently commented on SRDX shares. BidaskClub upgraded shares of Surmodics from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. ValuEngine upgraded shares of Surmodics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Lake Street Capital assumed coverage on shares of Surmodics in a research note on Friday, July 14th. They set a “buy” rating and a $40.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Surmodics presently has a consensus rating of “Hold” and an average target price of $40.00.

Shares of Surmodics (NASDAQ SRDX) traded down 0.17% during mid-day trading on Friday, hitting $30.25. 20,024 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $30.21 and a 200-day moving average price of $26.49. Surmodics has a 52 week low of $21.90 and a 52 week high of $32.80. The company has a market capitalization of $396.55 million, a price-to-earnings ratio of 65.90 and a beta of 0.86.

Surmodics (NASDAQ:SRDX) last released its earnings results on Thursday, August 3rd. The company reported $0.09 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.10. Surmodics had a return on equity of 7.28% and a net margin of 8.66%. The business had revenue of $17.80 million during the quarter, compared to analysts’ expectations of $15.98 million. During the same quarter last year, the firm posted $0.37 earnings per share. The firm’s revenue was down 11.0% on a year-over-year basis. On average, equities analysts anticipate that Surmodics will post $0.31 EPS for the current year.

In related news, CEO Gary R. Maharaj sold 5,000 shares of Surmodics stock in a transaction on Monday, August 7th. The stock was sold at an average price of $25.75, for a total transaction of $128,750.00. Following the sale, the chief executive officer now directly owns 126,807 shares in the company, valued at $3,265,280.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Joseph J. Stich sold 1,000 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $27.28, for a total value of $27,280.00. The disclosure for this sale can be found here. Insiders sold 6,801 shares of company stock worth $178,338 in the last 90 days. Corporate insiders own 6.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at

Surmodics Company Profile

Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.

Insider Buying and Selling by Quarter for Surmodics (NASDAQ:SRDX)

Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply